Hualan Vac(SZ:301207) Xin Lang Cai Jing·2026-02-11 07:18Group 1 - The core viewpoint of the news is that Hualan Vaccine's stock has experienced a decline, with a drop of 1.25% to 21.34 CNY per share, resulting in a total market capitalization of 12.826 billion CNY and a cumulative decline of 5.91% over four consecutive days [1] - Hualan Biological Vaccine Co., Ltd. is located in Xinxiang City, Henan Province, and was established on November 9, 2005. The company was listed on February 18, 2022, and its main business involves the research, production, and sales of human vaccines, with 98.11% of its revenue coming from vaccine products [1] Group 2 - From the perspective of Hualan Vaccine's top ten circulating shareholders, a fund under Southern Fund is among them. The Southern CSI 1000 ETF (512100) reduced its holdings by 8,700 shares in the third quarter, holding 1.6522 million shares, which accounts for 0.28% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) has a current scale of 78.996 billion CNY and has reported a year-to-date return of 8.61%, ranking 1564 out of 5569 in its category. Over the past year, it has achieved a return of 34.61%, ranking 1862 out of 4295 [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 98 days, with a total asset scale of 137.02 billion CNY. During this period, the best fund return was 251.88%, while the worst was -15.93% [2]